Akt-dependent regulation of NF- B is controlled by mTOR and Raptor in association with IKK by Dan, H. C. et al.
Akt-dependent regulation of NF-B
is controlled by mTOR and Raptor
in association with IKK
Han C. Dan,1 Matthew J. Cooper,1,2 Patricia C. Cogswell,1 Joseph A. Duncan,1 Jenny P.-Y. Ting,1
and Albert S. Baldwin1,2,3,4
1Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina
27599, USA; 2Curriculum in Genetics and Molecular Biology, University of North Carolina School of Medicine, Chapel
Hill, North Carolina 27599, USA; 3Department of Biology, University of North Carolina School of Medicine,
Chapel Hill, North Carolina 27599, USA
While NF-B is considered to play key roles in the development and progression of many cancers, the
mechanisms whereby this transcription factor is activated in cancer are poorly understood. A key oncoprotein
in a variety of cancers is the serine–threonine kinase Akt, which can be activated by mutations in PI3K, by
loss of expression/activity of PTEN, or through signaling induced by growth factors and their receptors. A key
effector of Akt-induced signaling is the regulatory protein mTOR (mammalian target of rapamycin). We show
here that mTOR downstream from Akt controls NF-B activity in PTEN-null/inactive prostate cancer cells
via interaction with and stimulation of IKK. The mTOR-associated protein Raptor is required for the ability of
Akt to induce NF-B activity. Correspondingly, the mTOR inhibitor rapamycin is shown to suppress IKK
activity in PTEN-deficient prostate cancer cells through a mechanism that may involve dissociation of Raptor
from mTOR. The results provide insight into the effects of Akt/mTOR-dependent signaling on gene
expression and into the therapeutic action of rapamycin.
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The transcription factor NF-B is broadly associated
with oncogenesis through its ability to control cell pro-
liferation and to suppress apoptosis. Additionally, the
NF-B pathway in cancer has been associated with con-
trol of metastasis and angiogenesis (Basseres and Bald-
win 2006; Karin 2006). The NF-B family is comprised of
five closely related members: p65/RelA, c-Rel, RelB, NF-
B1/p50, and NF-B2/p52 (Hayden and Ghosh 2004). NF-
B is activated downstream from signaling induced by
inflammatory cytokines such as TNF or IL-1, bacterial
endotoxin, and other innate immune response effectors,
and during T-cell activation. Control of NF-B is most
often regulated by the IKK complex through the phos-
phorylation of IB proteins with subsequent ubiquitina-
tion and degradation, promoting nuclear accumulation
of NF-B dimers (Hayden and Ghosh 2004). IKK is com-
prised of two catalytic subunits, IKK and IKK, and a
regulatory subunit, IKK/NEMO (Israel 2000; Bonizzi
and Karin 2004; Hayden and Ghosh 2004). Additionally,
phosphorylation of the RelA/p65 subunit is associated
with transcriptional activity of this NF-B subunit
(Hayden and Ghosh 2004).
NF-B has been reported to be activated by oncopro-
teins and by loss of tumor suppressors, but the mecha-
nisms associated with this activation are poorly under-
stood at present (Basseres and Baldwin 2006). For ex-
ample, it has been reported that the ser/thr kinase Akt
can promote NF-B activity. One group reported that
Akt functions downstream from TNF to directly phos-
phorylate IKK to activate NF-B (Ozes et al. 1999), al-
though this result was challenged (Delhase et al. 2000).
We and others reported (Madrid et al. 2001; Sizemore et
al. 2002) that Akt functions through IKK to promote the
transactivation potential and phosphorylation (RelA) of
NF-B. Akt is proposed to promote metastasis and an-
giogenesis through IKK in a manner that depends on NF-
B and -catenin activation (Agarwal et al. 2005).
Akt is an important regulator of cell growth and apo-
ptosis that is activated downstream from PI3K and is
inhibited by action of the tumor suppressor PTEN
(Downward 1998; Cantley and Neel 1999; Hay 2005).
Akt functions through its ability to phosphorylate a
number of key pro-oncogenic targets that promote cell
growth or inhibit apoptotic pathways (Hay 2005; Man-
4Corresponding author.
E-MAIL abaldwin@med.unc.edu; FAX (919) 966-0444.
Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.1662308.
1490 GENES & DEVELOPMENT 22:1490–1500 © 2008 by Cold Spring Harbor Laboratory Press ISSN 0890-9369/08; www.genesdev.org
ning and Cantley 2007). For example, Akt phosphory-
lates and inactivates Foxo proteins that are proapoptotic
through their ability to regulate the expression of genes
that encode proteins that promote cell death (Tran et al.
2003; see Hay 2005). Additionally, a primary effector of
Akt action is mTOR (mammalian target of rapamycin),
itself a ser/thr kinase that phosphorylates S6K and 4E-
BP1 to regulate translation (Fingar and Blenis 2004; Hay
and Sonenberg 2004). mTOR is associated with two com-
plexes (Bhaskar and Hay 2007): the rapamycin-sensitive
TORC1 complex that controls S6K phosphorylation, and
TORC2 (Hay and Sonenberg 2004), which is the PDK2
activity that controls ser473 phosphorylation of Akt
(Sarbassov et al. 2005). TORC1 is comprised of mTOR,
Raptor, and GL (Hara et al. 2002; Kim et al. 2002, 2003),
while TORC2 is comprised of mTOR, Rictor, and GL
(Sarbassov et al. 2005). The activation of TORC1 by Akt
involves the phosphorylation of TSC2, which relieves a
negative regulatory effect on mTOR controlled by the
GTPase Rheb (Inoki et al. 2003; Manning and Cantley
2003). Additionally, it has been reported that Akt can
regulate TORC1 through the control of cellular ATP lev-
els and AMPK activity (Hahn-Windgassen et al. 2005).
Recently, we showed that mTOR kinase activity in
PTEN-null/inactive prostate cancer cells is regulated
through an Akt-dependent interaction between IKK and
the mTOR–Raptor/TORC1 complex (Dan et al. 2007).
Both mTOR and PI3K/Akt are important in tumori-
genesis through their ability to promote cell growth and
responses to nutrients, and to suppress cell death (Viv-
anco and Sawyers 2002; Guertin and Sabatini 2005; Hay
2005; Majumder and Sellers 2005; Plas and Thompson
2005; Sabatini 2006; Shaw and Cantley 2006). Evidence
for the involvement in mTOR and Akt in tumorigenesis
has been provided with animal models using either con-
stitutively active Akt in association with rapamycin
treatment (Majumder et al. 2004) or deletion of PTEN in
combination with Akt knockout (Chen et al. 2006). Ad-
ditionally, Akt was shown to be highly dependent on
TORC1 (see below) for transformation properties (Skeen
et al. 2006). Although the anti-cancer and immunosup-
pressive drug rapamycin can function with FKBP12 to
rapidly target the inhibition of TORC1 through the dis-
sociation of raptor (see Sarbassov et al. 2006), its efficacy
is not universal in cancer (Sawyers 2003), with tumors
exhibiting expression defects in PTEN or VHL demon-
strating sensitivity to the drug (Neshat et al. 2001;
Podsypanina et al. 2001; Thomas et al. 2006).
Here we ask whether the Akt-dependent interaction
between IKK and mTOR found in PTEN-deficient pros-
tate cancer cells (Dan et al. 2007) controls NF-B-depen-
dent activity. The results show that the Akt-dependent
mTOR and IKK interaction stimulates IKK activity di-
rected toward the phosphorylation of IB and RelA/p65.
Inhibition of expression of mTOR or Raptor blocks NF-
B activation and suppresses NF-B-dependent gene ex-
pression. Additionally, rapamycin is shown to block NF-
B activity in prostate cancer cells with no PTEN activ-
ity, consistent with its inhibitory effects on TORC1.
These results provide new insight into the control of
NF-B activity downstream from Akt in certain cancer
cells and a more complete understanding of the effects of
rapamycin on certain cancer cells.
Results
Akt activity promotes an association between IKK
and mTOR in PTEN-null prostate cancer cells
We showed recently that elevated Akt activity in PC3
and LNCaP prostate cancer cells stimulates an associa-
tion between IKK and TORC1 to control the kinase
activity of mTOR (Dan et al. 2007). As shown previously
(Dan et al. 2007), siRNA-directed knockdown of Akt2 in
PC3 cells leads to the dissociation of IKK from the
mTOR complex (Fig. 1A). Knockdown of Akt1 in PC3
cells, while quantitatively effective, does not signifi-
cantly affect overall Akt activity in these cells and does
not lead to the dissociation of IKK from TORC1 (data
not shown). Although IKK is found in the TORC1 com-
plex in PC3 cells (Fig. 1B), knockdown of this IKK sub-
unit only weakly affects mTOR activity (Dan et al.
2007), indicating a distinct role for IKK in the regula-
tion of mTOR downstream from Akt. Additionally, IKK
is also found in the mTOR complex, as shown by coim-
munoprecipitation (Fig. 1B). The association of IKK and
IKK with the IKK/mTOR complex suggests the poten-
tial that NF-B activation could occur through this in-
teraction.
Size fractionation demonstrates that the IKK complex
is associated with mTOR–Raptor in PC3 cells
in a manner dependent on Akt
To extend the coimmunoprecipitation studies, PC3
cell extracts were analyzed by Superose 6 HPLC col-
umn chromatography (see the Materials and Methods).
Column fractions 9 through 19 were analyzed by immu-
Figure 1. Akt promotes mTOR association with IKK. (A) PC3
cells were transfected with siRNA control or siRNA to Akt2 as
indicated. The cells were lysed 48 h after transfection and the
lysates were immunoprecipitated with anti-mTOR, electropho-
resed on an SDS gel, and blotted with mTOR and IKK anti-
bodies, respectively (see Dan et al. 2007). Lysates were probed
with these antibodies plus anti-Raptor and anti-Akt2. (B) The
lysates were immunoprecipitated with anti-mTOR, anti-Rap-
tor, and IgG control; electrophoresed on an SDS gel; and blotted
with mTOR, Raptor, IKK, and IKK, and IKK antibodies.
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noblotting with antibodies for mTOR, Raptor, IKK,
IKK, and IKK (Fig. 2A). mTOR and Raptor were found
at highest levels in fractions 14–16, with lower levels in
fractions 13 and 17. This pattern of size-dependent dis-
tribution of mTOR and Raptor is very similar to that
reported by Guan and colleagues (Yang et al. 2006). IKK
and IKK were found at highest levels in fractions 13–15,
with IKK also found in fractions 13–15 (Fig. 2A). To
determine whether IKK and mTOR associate in these
column fractions, mTOR was immunoprecipitated from
fractions 9–19 and the immunoprecipitate was analyzed
by immunoblotting for IKK proteins (Fig. 2A). The re-
sults show that mTOR is associated with IKK subunits
at the highest levels in fraction 14, with detectable as-
sociation in fractions 13 and 15. Reciprocally, immuno-
precipitation with IKK antibody in fractions 13–15
shows that IKK is associated with mTOR/Raptor in frac-
tions 14 and 15 and only weakly in fraction 13 (data not
shown). In that immunoprecipitation experiment, there
is little Raptor associating with the IKK complex in frac-
tion 13. These results suggest that a large portion of IKK
is associated with mTOR in fractions 14 and 15, with
less association in fraction 13. To determine whether
Akt is required for the association between IKK and
mTOR, as measured through column fractionation and
immunoblotting, Akt2 was knocked down in PC3 cells.
As shown earlier, siRNA treatment was effective at sup-
pressing expression of Akt2, as compared with control
siRNA (Fig. 2B). Column fractionation of extracts from
siRNA control-treated and Akt siRNA treatment was
performed as described earlier and fractions were ana-
lyzed by immunoblotting for mTOR, Raptor, and the
IKK and IKK subunits. With the siRNA control treat-
ment of PC3 cells, fractionation followed by immuno-
blotting (Fig. 2B) was similar to that shown in Figure 2A.
In the Akt2 siRNA experiment, immunoblotting for
IKK and IKK demonstrates that fractions 14 and 15
have lost IKK and IKK following knockdown of Akt2
(Fig. 2B). Under these Akt2-deficient conditions, IKK
and IKK are largely localized in fraction 13. While it is
possible that IKK found in fractions 14 and 15 have as-
sociated with other proteins to shift to fraction 13, we
favor the concept that most of the IKK in fraction 13 was
not affected by Akt knockdown. This is based on results
showing that immunoprecipitation of IKK in fraction 13
only weakly pulls down mTOR with very little Raptor
(data not shown). That some mTOR remains in fractions
14 and 15 under the Akt siRNA knockdown conditions
suggests that either the loss of IKK subunits from the
mTOR complex leads to association with different pro-
teins to maintain a roughly similar mass or that only a
portion of the mTOR in those fractions was associated
with IKK, and that the portion of mTOR associated with
IKK was either destabilized or shifted to other fractions.
Consistent with the latter hypothesis, the mTOR-asso-
ciated protein Rictor is detected in fractions 14 and 15
(also seen in equivalent fractions in Yang et al. 2006) and
the mTOR–Rictor protein complex is presumably insen-
sitive to Akt knockdown. Overall, these results support
the coimmunoprecipitation experiments shown in Fig-
ures 1B and 2A, indicating that mTOR and IKK form an
Akt-dependent complex in PC3 cells.
mTOR regulates NF-B in a manner dependent on Akt
Based on the Akt-dependent interaction between mTOR/
Raptor and IKK subunits, we hypothesized that Akt
Figure 2. Size fractionation demonstrates that the IKK complex is associated with mTOR–Raptor. (A) PC3 cell lysates were separated
on a Superose 6 10/300 GL column. The indicated fractionations (top panel) and their mTOR immunoprecipitates (bottom panel) were
analyzed by immunoblotting with the indicated antibodies. (B, top panel) PC3 cell were transfected with control siRNA and siRNA
akt2, and Western blot shows the mTOR and Raptor expression. (Bottom panel) Lysates were separated on a Superose 6 10/300 GL
column and the indicated fractions were analyzed by immunoblotting with the indicated antibodies.
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regulation of NF-B activation is dependent on the inter-
action between mTOR and IKK. Support for this hypoth-
esis would provide a molecular mechanism to explain how
Akt could activate NF-B in a manner dependent on IKK
(Madrid et al. 2001; Sizemore et al. 2002). To address
whether mTOR can stimulate NF-B activity, PC3 and
LNCaP prostate cancer cells, as well as HeLa cells, were
transfected with an NF-B-dependent reporter and with an
empty vector or an expression vector for mTOR. Cell ex-
tracts were prepared and luciferase activity was quantified
for the different transfection conditions. The results of the
experiments demonstrate that PC3 and LNCaP cells ex-
hibit higher NF-B-dependent reporter activity as com-
pared with HeLa cells (Fig. 3A). Expression of mTOR in all
three cell types enhanced reporter activity, although HeLa
cells exhibited the lowest level of stimulation. To deter-
mine whether endogenous NF-B activity in PC3 cells is
controlled by TORC1, siRNA to mTOR or to Raptor was
utilized in parallel with a control siRNA. Knockdown of
mTOR or of Raptor strongly blocked NF-B-dependent re-
porter activity in PC3 cells, but was less effective in sup-
pressing HeLa cell-associated NF-B activity (Fig. 3B, left
panel). This latter result is consistent with the fact that
HeLa cells exhibit relatively low endogenous Akt activity.
As an important control, overexpression of mTOR under
mTOR siRNA knockdown conditions led to a partial res-
toration of NF-B-dependent luciferase activity (data not
shown). Additionally, knockdown of IKK or IKK sup-
pressed NF-B-dependent reporter activity in PC3 cells
(Fig. 3B, right panel). To determine whether Akt is impor-
tant for the observed NF-B activity in PC3 cells, siRNA to
Akt2 was utilized. Knockdown of Akt2 reduced NF-B-
reporter activity ∼70% in PC3 cells (Fig. 3C). Transfection
of mTOR induced NF-B activity ∼3.5-fold in PC3 cells,
and this response is suppressed with knockdown of Akt2
(Fig. 3C). This result indicates that basal NF-B activity
in PC3 cells is controlled by Akt and that the ability of
mTOR to activate NF-B in these cells is dependent, at
least partly, on Akt. To pursue this issue further, PTEN
was transfected into PC3 cells (PTEN-null) and NF-B-re-
porter activity was measured. Expression of PTEN reduced
basal NF-B activity in PC3 cells ∼50%, and similarly sup-
pressed the ability of mTOR to induce NF-B (Fig. 3D).
Additionally, PC3 or LNCaP cells were transfected with
the NF-B-dependent luciferase reporter, and cells were left
untreated or were exposed to either a PI3-kinase antagonist
(LY294002) or to rapamycin, an inhibitor of mTOR activ-
ity. Subsequently, cell extracts were prepared and lucifer-
ase measured. Both LY294002 and rapamycin reduced NF-
B-dependent reporter activity in PC3 and LNCaP cells
(Fig. 3E). Additionally, the results indicate that PC3 cells
appear to be more dependent on Akt and mTOR than
LNCaP cells, relative to the effects of the inhibitors on
NF-B-dependent reporter activity (Fig. 3E). To show that
the ability of mTOR to activate the NF-B-dependent re-
porter is IKK-dependent, PC3 were treated with siRNA
control or siRNA to IKK and luciferase activity measured.
The data reveal that siRNA to IKK blocks basal levels of
NF-B-dependent reporter activity and suppresses the abil-
ity of mTOR to induce the reporter (Fig. 3F). Overall, the
results from this group of experiments support the hypoth-
esis that Akt is important for NF-B-dependent activity in
prostate cells that are inactive for PTEN and that mTOR is
a critical intermediate in this signaling pathway.
Expression of NF-B-dependent genes in PC3 cells
is controlled by mTOR and Raptor
In order to determine whether mTOR and Raptor con-
tribute to the expression of genes known to be regulated
by NF-B, either mTOR or Raptor were knocked down
with siRNA in PC3 cells. RNA was isolated from these
cells and from cells exposed to control siRNA. Expres-
sion of Bcl-2, cIAP1, XIAP, IB, and cyclinD1 were mea-
sured with RT–PCR. GAPDH gene expression served as
a control for these experiments. Knockdown of mTOR
blocked expression of the experimental gene set ∼30%–
40%, while knockdown of Raptor reduced expression of
these genes ∼50% (Fig. 4). GAPDH expression was unaf-
fected by either siRNA treatment. These results, with
the data presented in Figure 2, demonstrate that mTOR
and Raptor signal to regulate endogenous NF-B-depen-
dent gene expression in PTEN-deficient prostate cancer
cells in a manner dependent on Akt.
mTOR and Raptor control NF-B DNA-binding
activity and RelA/p65 phosphorylation in PC3 cells
To determine mechanisms of regulation of endogenous
NF-B by mTOR and Raptor, extracts (whole cell and
nuclear) were prepared from PC3 cells treated with con-
trol siRNA or with siRNA for either mTOR or Raptor.
Electrophoretic mobility shift assays (EMSAs) were per-
formed with nuclear extracts using a class I MHC NF-
B-binding site probe. As shown in Figure 5A, siRNA
either to mTOR or to Raptor reduced NF-B DNA-bind-
ing activity, although knockdown of mTOR was more
effective in blocking the EMSA complex (Fig. 5A). Analy-
sis of SP1 binding in the extracts shows that there is
equivalent loading for the different experimental condi-
tions (Fig. 5A). The efficacy of knockdown of mTOR and
Raptor in these experiments is shown in Figure 5D.
Transfection of mTOR into PC3 cells led to an increase
in NF-B DNA-binding activity, as measured through
EMSA (Fig. 5B), and rapamycin treatment of PC3 cells
suppressed NF-B DNA-binding activity (Fig. 5C). Phos-
phorylation of both IB and RelA/p65 correlate with
IKK activity, and ultimately with NF-B activity
(Hayden and Ghosh 2004). Endogenous expression of ei-
ther mTOR or Raptor in PC3 was knocked down with
siRNA, and phosphorylation of RelA/p65 at ser536 or
IB at ser32/36 was measured with phospho-specific
antibodies. Results from this experimentation showed
that knockdown of mTOR or of Raptor each blocked
phosphorylation of RelA/p65 and of IB (Fig. 5D). Ad-
ditionally, knockdown of IKK, IKK, or Akt2 in PC3
cells reduced p65 and IB phosphorylation (Fig. 5 E,F).
Transfection of mTOR into PC3 cells induced RelA/p65
ser536 phosphorylation (Fig. 5F), and LY294002 and rapa-
mycin individually suppressed RelA/p65 phosphoryla-
tion (Fig. 5G). In the latter experiment, LY and rapamycin
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cin each blocked mTOR activity as detected through
phosphorylation of S6K using the T389 phospho-specific
antibody. These experiments show that phosphorylated
Akt (S473) is increased following rapamycin treatment,
consistent with the findings of others (O’Reilly et al.
2006; Shah and Hunter 2006), which show that S6K
feeds back to block IRS-1 through phosphorylation. In-
hibition of this response can lead to growth factor-
induced PI3K and Akt activation. In summary, these ex-
periments indicate that mTOR and Raptor, through an
Figure 3. mTOR/Raptor positively regulates NF-B-dependent luciferase reporter activity in PTEN-deficient prostate cancer cells in
a manner dependent on Akt. (A) PC3, LNCaP, and HeLa cells were transfected with 700 ng of mTOR expression vector or empty vector
plus 200 ng of 3× B luciferase reporter and 30 ng of pRL-SV40 (Renilla reporter control). Cells were harvested after 24 h and luciferase
assays were performed (measured as relative luciferase/luminescence units). (B) PC3 and HeLa cells were transfected with the
NF-B-dependent luciferase reporter and control siRNA, or siRNA to mTOR, Raptor, IKK, or IKK, as indicated. Luciferase assays
were performed as in A after 24 h. Levels of luciferase are compared with the siRNA control for each cell type. Western blot shows
the mTOR and Raptor protein levels. (C) PC3 cells were transfected the NF-B-dependent luciferase reporter and either empty vector
or mTOR expression vector, and with control siRNA, or siRNA to Akt2, as indicated. Luciferase assays were performed as in A after
48-h transfection of siRNA. (D) PC3 cells were cotransfected with mTOR and/or PTEN with 3× B luciferase reporter and 30 ng of
pSV40-RL as indicated. Luciferase assays were performed as in A after 24 h transfection. (E) PC3 and LNCaP cells were transfected as
described above, and then treated with LY294002 (3 h) or Rapamycin (3 h) 24 h after transfection. Luciferase assays were performed
as in A. SD is shown and is representative of at least three experiments. (F) PC3 cells were transfected with control siRNA, or siRNA
to IKK, as indicated. The NF-B-dependent luciferase reporter and either empty vector or mTOR expression were transfected 24 h
after siRNA transfection, and luciferase assays were performed as in A after 48-h transfection of siRNA. Immunoblotting for expressed
proteins is shown. Experiments were performed in triplicate and SD is shown.
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Akt-dependent pathway, control NF-B activity in PC3
prostate cancer cells both at the level of IB and RelA/
p65 phosphorylation.
mTOR controls IKK activity downstream from Akt
The regulation of IB and RelA/p65 phosphorylation by
mTOR and Raptor suggests that these proteins may ac-
tivate IKK. In order to address this hypothesis, several
different experiments were performed. siRNA experi-
ments in PC3 cells revealed that knockdown of either
mTOR or Raptor reduced endogenous phosphorylation
of IKK and IKK in their activation loops (Fig. 6A). Us-
ing the same knockdown approach, immunoprecipitated
IKK (via immunoprecipitation of IKK) demonstrated re-
duced IKK in vitro kinase activity using IB as a sub-
strate (Fig. 6B). Immunoprecipitated IKK, IKK, and
IKK demonstrated reduced in vitro phosphorylation of a
C-terminal fragment of RelA/p65 when either mTOR or
Raptor were knocked down with siRNA (Fig. 6C). Myc-
tagged mTOR was transfected into PC3 cells and endog-
enous IKK, IKK, or IKK was immunoprecipitated and
used in an in vitro kinase assay using recombinant IB
as a substrate. Results from this experiment demonstrate
that expression of mTOR stimulates IKK activity (Fig.
6D). Similarly, immunoprecipitated IKK subunits dem-
onstrated enhanced in vitro activity against recombinant
C-terminal RelA/p65 following mTOR expression (Fig.
6E). To further analyze mTOR-dependent IKK activity,
column fractions 14–17 (see Fig. 2A) were immunopre-
cipitated with mTOR, and an IKK assay was performed
using recombinant IB as a substrate (Fig. 6F). These
fractions were chosen since fractions 14 and 15 exhibit
mTOR–IKK association, while fraction 16 exhibits
mTOR and Raptor but not significant levels of IKK sub-
units. Fraction 17 is relatively weak for all of these pro-
teins. Immnunoprecipitation of mTOR reveals that frac-
tion 14 has the highest IKK activity, while fraction 15 is
reduced, consistent with lower levels of mTOR-associ-
ated IKK. Fraction 16, although it has mTOR and Raptor,
has very low levels of associated IKK and correspond-
ingly low IKK activity. Fraction 17 exhibits no IKK ac-
tivity following mTOR immunoprecipitation. These re-
sults demonstrate that mTOR-associated IKK in PC3
cells exhibits activated kinase activity.
Rapamycin inhibits IKK activity, potentially through
dissociation of Raptor from the mTOR complex
Rapamycin suppresses mTOR activity through interac-
tion with FKBP12 and the subsequent interaction of the
FKBP12/rapamycin complex with mTOR (see Sawyers
2003). Thus, we considered the possibility that rapamy-
cin would inhibit IKK activity in PTEN-deficient cells.
PC3 cells were left untreated or were treated with rapa-
mycin for 2 h. IKK was immunoprecipitated and used
in an in vitro kinase assay as described above. The re-
sults from this experiment indicate that rapamycin sup-
presses IKK activity (Fig. 7A), consistent with our find-
ings regarding the ability of mTOR to regulate IKK in
PC3 cells. Additionally, rapamycin blocked RelA/p65
phosphorylation that occurs constitutively in PC3 pros-
tate cancer cells. Rapamycin was also shown to inhibit
S6K phosphorylation, consistent with the effects of rapa-
mycin on TORC1. Rapamycin has been shown to disrupt
Raptor from mTOR in the TORC1 complex (Sarbassov et
al. 2006). We asked whether rapamycin would disrupt
IKK from TORC1, potentially explaining the effects of
rapamycin on PC3 cell-associated NF-B activity. PC3
cells were untreated or were treated with rapamycin for
2 h, and mTOR was immunoprecipitated. The immuno-
precipitate was tested for the presence of Raptor, mTOR,
and IKK by immunoblotting. Results indicate that rapa-
mycin dissociates Raptor from the mTOR/TORC1 com-
plex, consistent with the results of Sarbassov et al. (2006),
but does not dissociate IKK. These results, which are con-
sistent with the siRNA knockdown experiments shown
above, support the hypothesis that Raptor is required in
association with mTOR to regulate IKK activity and down-
stream NF-B activation in PC3 cells. We recognize that
rapamycin could affect a distinct signaling step in the IKK
pathway, although rapamycin does not significantly block
TNF-induced NF-B activation in several cell types or con-
stitutive activation of NF-B in cancer cells that exhibit
low Akt activity (data not shown). The results also indicate
that Raptor is not required for association of IKK with the
mTOR complex.
Discussion
NF-B activation induced downstream from cytokines
and other inflammatory and immune regulators involves
the activation of IKK by upstream mediators such as
RIP2 and Tak1, followed by phosphorylation and degra-
dation of IB in association with phosphorylation of
Figure 4. mTOR/Raptor is involved in control of NF-B target
gene expression in PC3 cells. PC3 cells were transfected with
control siRNA, or siRNA to mTOR or Raptor, as indicated.
RNA was extracted 48 h after transfection and RT–PCR (see the
Materials and Methods) was performed to assess changes in
mRNA levels of NF-B target gene expression. A representative
experiment from among three others is shown.
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RelA/p65 (Bonizzi and Karin 2004; Hayden and Ghosh
2004). In these signaling pathways, NF-B accumulates
in the nucleus and binds to target sequences to control
transcriptional responses. In cancer cells, NF-B activa-
tion has been described to occur downstream from on-
coproteins such Ras and BCR-ABL, but specific signaling
mechanisms involved with the induction of this tran-
scription factor are poorly characterized at present
(Basseres and Baldwin 2006). Akt, a ser–thr kinase that
exhibits elevated activity in a number of cancers (Hay
2005), has also been reported to activate NF-B, but,
again, this response is not well understood. Our group
and that of George Stark reported that Akt utilizes IKK
to activate NF-B transactivation potential and induce
RelA/p65 phosphorylation (Madrid et al. 2001; Sizemore
et al. 2002). Here we explore a mechanism to explain the
origin of NF-B activity downstream from constitutively
activated Akt in PTEN-deficient prostate cancer cells.
Previously, we showed that IKK is an important regu-
lator of mTOR activity, associated with TORC1, in
PTEN-deficient PC3 and LNCaP cells (Dan et al. 2007).
Another group showed that IKK can induce mTOR, in
an Akt-independent manner, through direct phosphory-
lation of TSC1 (Lee et al. 2007). Our original studies
indicated that constitutively active Akt induces an as-
sociation between IKK and the TORC1 complex in
these cells and that IKK induces mTOR kinase activity
directed against S6K and 4E-BP1. It was found that IKK
also associates with TORC1 in an Akt-dependent man-
ner (see Fig. 1B), but that knockdown of IKK expression
only weakly affected mTOR kinase activity (Dan et al.
2007), indicating a largely unique role for IKK in this
process. Based on those observations, we hypothesized
that the interaction between mTOR and IKK, while con-
trolling mTOR kinase activity in PTEN-deficient pros-
tate cancer cells, may reciprocally stimulate IKK activity
to induce NF-B. The experiments presented in this
study strongly support this hypothesis. Using expression
of mTOR and knockdown of endogenous mTOR and
Raptor, we demonstrate that TORC1 regulates NF-B at
the level of DNA binding, RelA/p65 phosphorylation,
and reporter and endogenous gene expression. Immuno-
precipitation and in vitro kinase assays demonstrate that
mTOR and Raptor induce IKK activity in an Akt-depen-
dent manner. The results provide a molecular mecha-
nism to explain how Akt regulates NF-B activity, at
Figure 5. Akt/mTOR/Raptor pathway promotes NF-B DNA-binding activity and RelA/p65 and IB phosphorylation. (A) PC3 cells
were transfected with control siRNA, or siRNAs to mTOR or Raptor, as indicated. EMSAs were performed using nuclear extracts from
cells lysed 48 h after transfection. A radiolabeled SP1 probe was used to normalize protein loading. (B) PC3 cells were transfected with
mTOR expression vector or empty vector (control). EMSAs were performed using nuclear extracts from cells 48 h after transfection.
(C) PC3 cells were treated with Rapamycin (100 nM) or DMSO for 2 h. Electrophoretic gel shift assays were performed using nuclear
extracts from the cells as in A. (D,E) PC3 cells were transfected with siRNA control or other siRNAs, as indicated (IKK, IKK, mTOR,
Raptor, Akt1, or Akt2). The cells were lysed 48 h after transfection and the levels of IKK, IKK, mTOR, Raptor, Akt1, Akt2, and
-tubulin, and of endogenous phosphorylation of P65, Akt, and IB were determined by immunoblotting with the indicated anti-
bodies. (F) PC3 cells were transfected with myc-mTOR wild type or vector control as indicated. Cell lysates were generated and blotted
with phospho-p65-S536, p65, S6K and myc tag, and actin antibodies, as indicated. (G) PC3 cells were treated with Rapamycin (100 nM)
or DMSO for 2 h. Cell lysates were generated and blotted with the antibodies as indicated. Experiments are representative of three
replicates.
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least in PTEN-deficient prostate cancer cells. The data
also provide a mechanism to explain the ability of
mTOR to promote cell survival, since NF-B is known to
regulate the expression of genes that suppress apoptosis.
What is the nature of the IKK–mTOR complex in
PC3 cells? Using PC3 cell lysates, mTOR antibody
immunoprecipitates mTOR and Raptor, as expected, and
each of the three IKK subunits. This complex (or com-
plexes) is found at the highest levels in column fractions
14 and 15, with a molecular mass of >700 kD (Fig. 2). The
relative size of the IKK complex in PC3 cells is similar to
what has been found in other fractionation studies (Chen
et al. 2002). Additionally, the distribution of mTOR and
Raptor in these fractions is very similar to that reported
by Guan and colleagues (Yang et al. 2006). It is unclear at
present whether this complex contains other regulatory
molecules known to be associated with IKK (such as
cdc37 and Hsp90) (see Chen et al. 2002) or with mTOR
(such as GL). The stability of this complex requires
Akt, as knockdown of Akt2 caused a disappearance of
IKK and IKK from column fractions 14 and 15, with
IKK in column fraction 13 largely unaffected. mTOR
and Raptor did not appreciably change in their localiza-
tion in fractions 14 and 15 following knockdown of
Akt2, suggesting that the loss of IKK subunits from the
complex leads to the association with other proteins
such that the relative size of the mTOR complex is not
altered in a significant manner, or that only a portion of
mTOR in these fractions is associated with IKK. Relative
to the latter point, mTOR and IKK subunits that are
dissociated following knockdown of Akt2 may distribute
to other fractions or may be unstable. Further studies are
required to understand the molecular components in the
Akt-dependent mTOR–IKK complex and in the remain-
ing complexes when Akt activity is suppressed.
The interplay between Akt, mTOR, and IKK is likely
to be complex. Akt is known to activate mTOR through
phosphorylation and inactivation of TSC2 (see above),
thus it is possible that inactivation of TSC2 and loss of
its negative control of Rheb leads to an association be-
tween IKK and mTOR. Recent work indicates that TSC2
is involved in NF-B activation (Ghosh et al. 2006), con-
sistent with a potential placement of TSC2 upstream of
mTOR/IKK and downstream from Akt. Our studies with
rapamycin indicate that this drug leads to dissociation of
Raptor from the TORC1 complex (as originally shown by
Figure 7. Rapamycin inhibits IKK activity and dissociates Rap-
tor from the mTOR complex. (A) PC3 cells were treated with
rapamycin (100 nM) or DMSO for 2 h. Cell lysates were gener-
ated and IKK activity was measured by in vitro IKK kinase assay
using GST-IB as substrate. (B) PC3 cells were treated with
rapamycin as in A. Cell lysates were immunoprecipitated with
anti-mTOR and blotted with mTOR, Raptor, and IKK antibod-
ies, respectively.
Figure 6. mTOR/Raptor pathway enhances IKK kinase activ-
ity in Akt-active cells. (A) Depletion of mTOR and Raptor with
siRNA decreases phosphorylation of IKK and IKK in their
activation loops. (B,C) Depletion of mTOR and Raptor with
siRNA decreases IKK activity in PC3 cells, as measured by in
vitro IKK kinase assay using GST-IB or GST-p65 as substrate.
(D,E) PC3 cells were transfected with myc-mTOR or vector con-
trol. Endogenous IKK, IKK, or IKK were immunoprecipi-
tated and IKK kinase activity directed toward GST-p65 was de-
termined in the immunoprecipitates. (F) PC3 cell lysates were
separated on a Superose 6 10/300 GL column. Anti-mTOR pre-
cipitates from the indicated fractionations were incubated with
GST-IB (1–54) and 32P--ATP for kinase assay and were ana-
lyzed by immunoblotting with the indicated antibodies.
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Sarbassov et al. 2006) but not the dissociation of IKK
(Fig. 7B). This result suggests that Raptor is not required
for IKK to associate with TORC1 in PTEN-deficient
prostate cancer cells. Furthermore, how active TORC1
may induce IKK activity is unclear, although phosphor-
ylation of an IKK subunit by mTOR is a possibility. In
this regard, we have been unable to show that mTOR
phosphorylates IKK in vitro, although knockdown of
mTOR or Raptor block phosphorylation of IKK subunits
in their activation loops (see Fig. 6A). Additionally, the
observations that knockdown of Raptor or loss of the
association between Raptor and mTOR following rapa-
mycin treatment leads to an inhibition of NF-B activa-
tion is consistent with the role of Raptor as a key regu-
lator of TORC1 activity, including the NF-B activation
response.
Rapamycin is a molecule that blocks mTOR activity
through a mechanism involving interaction with FKBP12
and subsequent interaction with TORC1 to inhibit mTOR
kinase activity (see Sawyers 2003). Rapamycin and its
analogs are used to prevent transplant rejection and to
suppress restenosis after angioplasty; additionally, its ef-
fects on cancer cells in vitro are consistent with a poten-
tial as an anti-cancer drug (Sawyers 2003; Guertin and
Sabatini 2005; Sarbassov et al. 2006). However, it is clear
that only a subset of cancer patients respond to rapamy-
cin (Sawyers 2003). Interestingly, tumors that are defi-
cient in the tumor suppressors PTEN or VHL appear to
exhibit sensitivity to rapamycin (Neshat et al. 2001;
Podsypanina et al. 2001; Thomas et al. 2006). Our results
indicate that NF-B activity is suppressed by rapamy-
cin in PTEN-deficient prostate cancer cell lines, raising
the potential that the inhibitory effects of rapamycin on
NF-B in PTEN-deficient cells contributes to the thera-
peutic benefit of this drug in this particular cancer set-
ting.
Akt serves as an essential signaling node downstream
from several upstream regulators, including cytokines
and growth factors (Manning and Cantley 2007). Via its
kinase activity, Akt controls cell survival, proliferation,
and growth. Within this group of properties, suppression
of apoptosis is a key function of Akt, which is likely to
play an important role in the pro-oncogenic functions of
Akt. In this respect, Akt phosphorylates and inhibits the
BH3-only, proapoptotic protein BAD (see Manning and
Cantley 2007). Also, Akt phosphorylates FOXO tran-
scription factors to induce their nuclear export, suppress-
ing their proapoptotic function (Tran et al. 2003). Given
the key anti-apoptotic functions ascribed to NF-B (see
Basseres and Baldwin 2006), it is likely that NF-B acti-
vation downstream from Akt functions to promote cell
survival. Previous evidence for this was provided by
Madrid et al. (2001). Our data indicate that Akt, at least
in the setting of loss of PTEN function, promotes IKK-
dependent activation of NF-B via mTOR and Raptor,
which controls the expression of certain key anti-apo-
ptotic genes (see Fig. 4). In this pathway, TORC1 would
promote cell survival through a mechanism that is inde-
pendent of the traditional translational-dependent path-
ways associated with mTOR activity. Thus, our results
provide insight into new regulatory functions of Akt and
mTOR.
Materials and methods
Cell culture and reagents
HeLa and the prostate cancer cell lines PC3 and LNCaP were
from American Type Culture Collection. All cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 2 mM glutamine,
and 100 U/mL penicillin and streptomycin (Gibco). The re-
agents were obtained from the following sources: Protease and
phosphatase inhibitor cocktails were from Roche; CHAPS was
from Pierce; rapamycin was from Calbiochem; LY294002 was
from Cell Signaling; and protein A and protein G agarose beads
were from Invitrogen Life Technologies. The radiochemicals
used were obtained from New England Nuclear. Recombinant
GST-p65/RelA C-terminal fragment was provided by Dr. Marty
Mayo (University of Virginia).
Antibodies
Antibodies were obtained from the following sources: Antibod-
ies against IKK-, IKK-, mTOR, Akt1, and Akt2 were obtained
from Upstate Biotechnology. Anti-Raptor and anti-Rictor anti-
bodies were obtained from Bethyl Laboratories. Anti-actin was
obtained from Calbiochem. The anti-myc (9E-10) and control
rabbit IgG, as well as HRP-labeled anti-mouse and anti-rabbit
secondary antibodies were from Santa Cruz Biotechnology. All
other antibodies were from Cell Signaling.
Transfections
Transfections were performed using Polyfect Transfection Re-
agent (Qiagen) or Lipofectamine and Plus (Invitrogen) following
the manufacturer’s instructions. Briefly, 3–4 h after transfec-
tion, cells were recovered in full serum for 36 h or in full serum
for 24 h and then serum-starved for 16–24 h as indicated.
RNAi
siRNA SMARTpool IKK (catalog #M-003473), IKK (catalog
#M-003503), Akt1 (catalog #M-003000), Akt2 (catalog
#M-003001), and mTOR (catalog #M-003008) were from Dhar-
macon. Each of these represents four pooled SMART-selected
siRNA duplexes that target the indicated mRNA. siRNA to
Raptor was from Dharmacon following the article (Kim et al.
2002). PC3 or HeLa cell lines cells were transfected with indi-
cated SMARTpool siRNA or nonspecific control pool using
DharmaFECT 1 reagent (Dharmacon) according to the manu-
facturer’s instructions. Briefly, 20 nM final concentration of
siRNA was used to transfect cells at 60%–70% confluency.
Twenty-four hours after transfection, cells were recovered in
full serum or were serum-starved 16 h before harvest. Cells were
harvested 48–72 h after siRNA transfection.
Size exclusion chromatography
Lysates were prepared from PC3 cells as described above. A
Superose 6 10/300 GL column (GE Healthcare) was equilibrated
in lysis buffer containing 50 mM Tris HCl (pH 7.5), 120 mM
NaCl, 1 mM NaVO3, 10 mM NaF, 1 mM DTT, 1 mM PMSF, 10
µg  mL−1 Aprotinin, and 10 µg  mL−1 Leupeptin using a Bio-
Rad Duoflow liquid chromatography system. Lysate containing
4 mg of total protein was applied to the column and separated,
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running lysis buffer at 0.4 mL/min. The volume of elution for
each molecular weight was determined using size exclusion
chromatography standards (Bio-Rad). Fractions were subjected
to SDS-PAGE and immunoblot analysis with antibodies di-
rected toward the indicated proteins.
Cell lysis, immunoblotting, and coimmunoprecipitations
Cells were lysed and immunobotted as described (Kim et al.
2002) with minor modifications. Briefly, cells grown on 100-
mm dishes were rinsed twice with cold PBS and then lysed on
ice for 20 min in 1 mL of lysis buffer (40 mM Hepes at pH 7.5,
120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM
glycerophosphate, 50 mM NaF, 0.5 mM orthovanadate, EDTA-
free protease inhibitors [Roche]) containing 1% Triton X-100.
After centrifugation at 13,000g for 10 min, samples containing
20–50 µg of protein were resolved by SDS-PAGE, and proteins
were transferred to Pure Nitrocellulose Membrane (Bio-Rad),
blocked in 5% nonfat milk, and blotted with the indicated an-
tibodies.
For immunoprecipitation experiments, the lysis buffer con-
tained 0.3% CHAPS instead of 1% Triton. Four micrograms of
the indicated antibodies were added to the cleared cellular ly-
sates and incubated with rotation for 6–16 h. Then, 25 µL of
protein G-agarose were added and the incubation continued for
1 h. Immunoprecipitates captured with protein G-agarose were
washed three times with the CHAPS Lysis Buffer and two times
by wash buffer A (50 mM Hepes at pH 7.5, 150 mM NaCl), and
boiled in 4× SDS sample buffer prior to electrophoresis and im-
munoblotting.
In vitro IKK Assay
PC3 cells were grown in 100-mm dishes for 48 h in DMEM
containing 10% FBS and lysed in 1 mL of lysis buffer with 0.3%
CHAPS. Half of the total cell lysate was incubated with anti-
IKK, IKK, or IKK antibody for 6–12 h, followed by another
hour of incubation with 25 µL of protein G agarose beads. Im-
munoprecipitates were washed three times with lysis buffer,
and once with IKK kinase buffer without ATP (20 mM Hepes at
pH 7.7, 2 mM MgCl2, 2 mM MnCl2, 10 mM -glycerophos-
phate, 10 mM NaF, 10 mM p-Nitrophenyl Phosphate [PNPP],
300 µM orthovanadate, 1 mM Benzamidine, 2 mM PMSF, 1 mM
DTT, 10 µg/mL aprotinin, 1 µg/mL Leupeptin, 1 µg/mL pep-
statin, 1 mM DTT). Kinase assay toward recombinant GST-IB
(amino acids 1–54) or GST-p65/RelA C-terminal fragment using
washed immunoprecipitates was performed for 45 min at 30°C
in 30 µL of IKK kinase buffer with 10 µM ATP and [-32P]ATP
(0.5 µCi for per kinase reaction). To stop the reaction, 8 µL of 4×
SDS sample buffer was added to each reaction, which was boiled
for 10 min. The reaction was then separated by 4%–12% SDS-
PAGE and transferred to PVDF membrane. 32P incorporated
into GST-IB or GST-p65/RelA C-terminal fragment was as-
sessed by autoradiography.
Reporter assays
Cells were seeded in six-well plates and were transfected with
700 ng of total DNA using Lipofectamine and Plus (Invitrogen)
following the manufacturer’s instructions. In all, 200 ng of 3×
B luciferase reporter and 50 ng of pRL-SV40 (Renilla reporter
control) DNA were cotransfected. Cells were harvested after 24
h of transfection, and luciferase assays were performed using the
Dual Luciferase Assay System (Promega). All transfections were
performed in triplicate.
EMSA
EMSAs were performed as described previously (Mayo et al.
1997).
RNA extraction and real-time PCR
RNA extraction and real-time PCR were performed as described
previously (Steinbrecher et al. 2005).
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